• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pavmed to drop 510(k), pursue de novo pathway for PortIO infusion system

October 4, 2017 By Sarah Faulkner

PavmedPavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed with the SEC yesterday.

The move is based on a recommendation from the FDA, the company said.

The company’s 510(k) relied upon substantial equivalence to a previously-approved predicate device with an indication for use for up to 24 hours. Pavmed met with the FDA in July this year to discuss the issue of substantial equivalence, the company said.

The FDA gave Pavmed feedback at that meeting and the company narrowed the indications for its PortIO system and included a needle in the system’s kit.

But the FDA has told Pavmed that PortIO is not substaintially equivalent to the proposed predicate, despite these changes, and has instead encouraged the company to pursue a de novo classification.

The New York-based company said it plans to follow a de novo pathway for PortIO under a broader indication, for up to seven days. Pavmed also reported that it hopes to land a pre-submission meeting with the FDA.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: PAVmed

IN CASE YOU MISSED IT

  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS